What is Cosentyx?
Cosentyx (secukinumab) is a monoclonal antibody that targets interleukin-17A (IL-17A), a protein involved in inflammation. Novartis manufactures it for treating moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa in adults and children.[1]
How does Cosentyx work?
It binds specifically to IL-17A, blocking its interaction with receptors on immune cells. This reduces inflammation in autoimmune conditions like psoriasis and arthritis.[1]
Common uses and approvals
FDA approved Cosentyx in 2015 for plaque psoriasis and psoriatic arthritis. Later approvals include ankylosing spondylitis (2016), non-radiographic axial spondyloarthritis (2019), and hidradenitis suppurativa (2023). Dosing starts with loading doses, then 300 mg monthly via subcutaneous injection for most adults.[1]
Who makes Cosentyx and what does 'ab' mean?
Novartis develops and markets Cosentyx globally. 'Ab' refers to 'antibody,' as in monoclonal antibody (mAb), its biologic class.[1]
When do Cosentyx patents expire?
Key U.S. patents for secukinumab expire between 2026 and 2032, with composition-of-matter patent US8119147 expiring February 2030. Check DrugPatentWatch.com for litigation updates and Paragraph IV challenges from biosimilar developers.[2]
How much does Cosentyx cost?
U.S. wholesale acquisition cost is about $6,000-$7,000 per monthly dose (300 mg), varying by indication and insurance. Patient assistance programs from Novartis can lower costs.[1]
What side effects do patients report?
Upper respiratory infections (common), diarrhea, and injection-site reactions occur in trials. Rare risks include serious infections, IBD flares, and hypersensitivity. Long-term data show sustained efficacy but monitor for tuberculosis reactivation.[1]
How does Cosentyx compare to other biologics?
| Drug | Target | Psoriasis Efficacy (PASI 90 at 12 weeks) | Key Difference |
|------|--------|------------------------------------------|---------------|
| Cosentyx | IL-17A | ~70-80% | Faster skin clearance than TNF inhibitors |
| Stelara (ustekinumab) | IL-12/23 | ~60-70% | Broader approval in Crohn's |
| Tremfya (guselkumab) | IL-23 | ~70-80% | IL-23 specific, similar joint efficacy |
| Humira (adalimumab) | TNF | ~50-60% | Cheaper biosimilars available |
Cosentyx often shows quicker response in psoriasis head-to-head trials vs. TNFs.[1][3]
Are biosimilars for Cosentyx available?
No U.S. biosimilars yet due to ongoing patent disputes. First approvals possible post-2030; Europe has earlier entries expected by 2026.[2]
Who should avoid Cosentyx?
Active infections, untreated tuberculosis, or IBD history. Not for live vaccines during treatment.[1]
[1]: FDA Label for Cosentyx
[2]: DrugPatentWatch.com - Cosentyx Patents
[3]: NEJM - Secukinumab vs. Ustekinumab Trial